ENGLISH :
Since 1993 many seizures of 1-phenylethylamine have been made in several European countries. It was originally thought that 1-phenylethylamine had been made in error, but later information suggested that it had been prepared delibera[...]

2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol) are psychoactive substances, sold primarily over the Internet and in 'head' shops as 'legal highs', 'rese[...]

Substituted phenethylamines are a class of designer drugs that hold a significant position in the drug abuse market. The most important substances within this class appear to be 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and its novel derivative[...]

Substituted phenethylamines are a class of designer drugs that have recently emerged in the drug abuse market. Such substances remain legal to use, possess, and supply until these compounds become classified as scheduled. 2C-I-NBOMe or 25I-NBOMe[...]

This document is divided into five chapters, each summarizing an area of MDMA research: clinical studies; information on illicit users, neurotoxicity research in animals; neurotoxicity research in humans; and adverse events in illicit users. App[...]

The illicit marketplace of substances of abuse continually offers for sale legal alternatives to controlled drugs to a large public. In recent years, a new group of designer drugs, the synthetic cathinones, has emerged as a new trend, particular[...]

In recent years, the spread of new psychoactive substances has dramatically increased in term of availability of both number of compounds and chemical families. In November 2012, 4,4'-Dimethylaminorex (4,4'-DMAR), a novel synthetic stimulant, wa[...]

This report presents the data and findings of the risk assessment on the new psychoactive substance, 4-methylamphetamine, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and use of this stimulant drug[...]

This report presents the data and findings of the risk assessment on the new psychoactive substance, 4-methylamphetamine, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and use of this stimulant drug[...]